Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma

Nature Reviews Clinical Oncology

Volumn 12, Issue 11, 2015, Pages 625-626

  Sullivan, Ryan J ^a   Flaherty, Keith T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GP100 VACCINE; IPILIMUMAB; NIVOLUMAB; PD 1 ANTIBODY; PEMBROLIZUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ADVERSE DRUG REACTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; HUMAN; MELANOMA; MONOTHERAPY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; IMMUNOTHERAPY; METASTASIS; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84946482706     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.170     Document Type: Short Survey

References (10)

1. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
2. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
3. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
4. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
5. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013).
6. Robert, C. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109-1117 (2014).
7. Ribas, A. et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908-918 (2015).
8. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
9. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
10. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).